(Oslo, Norway, 13 January 2017) Reference is made to a stock exchange announcement by Solon Eiendom ASA ('Solon' or the 'Company', ticker 'SOLON') on 12 January 2017 regarding approval of the Company's prospectus dated 12 January 2017 (the 'Prospectus'), listing of new shares and further information on a subsequent offering of shares in the Company.

SOLON EIENDOM ASA

STOCK EXCHANGE ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SWITZERLAND OR THE UNITED STATES

Solon Eiendom ASA - Publication of prospectus, listing of new shares and start of subscription period

(Oslo, Norway, 13 January 2017) Reference is made to a stock exchange announcement by Solon Eiendom ASA ('Solon' or the 'Company', ticker 'SOLON') on 12 January 2017 regarding approval of the Company's prospectus dated 12 January 2017 (the 'Prospectus'), listing of new shares and further information on a subsequent offering of shares in the Company.

The Prospectus has now been published in accordance with applicable law and will, subject to regulatory restrictions in certain jurisdictions, be available on the following websites: www.bionorpharma.com, www.dnb.no/emisjoner, www.arctic.com/secno/offerings and www.sb1markets.no. Hard copies of the Prospectus may be obtained by contacting the Company (telephone: +47 22 29 66 90), DNB Markets (telephone: +47 23 26 81 01), Arctic Securities (telephone: +47 21 01 30 40) or Sparebank 1 Markets (telephone: +47 +47 24 14 74 00).

The 6,666,666,666 new shares issued as transaction consideration to the sellers of shares in Solon Eiendom AS and the 1,000,000,000 new shares issued in a private placement announced on 24 November 2016 have assumed the regular ISIN of the Company's shares under the ticker 'SOLON' and are tradable on Oslo Børs as of today, 13 January 2017.

The subscription and trading period in the Company's offering of 666,666,666 new offer shares in a subsequent offering will start at 09:00 CET today, 13 January 2017. For further information about the subsequent offering, please refer to the Company's stock exchange announcement as of yesterday, 12 January 2017.

DNB Markets, a part of DNB Bank ASA, Arctic Securities AS and SpareBank 1 Markets are engaged as managers for the Subsequent Offering.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
Simen Thorsen
Chairman of the Board, Solon Eiendom ASA
E-mail: st@soloneiendom.no
Cell Phone: +47 918 86 886

Andreas Martinussen
Chief Executive Officer, Solon Eiendom ASA
E-mail: am@soloneiendom.no
Cell Phone: +47 400 00 405

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region. Solon Eiendom was established in 2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. The company has since its incorporation delivered 570 units with a corresponding sales value of close to NOK ~3 billion and sold more than 800 units with a total sales price of more than NOK ~4 billion.

Important Information
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan, Hong Kong or the United States (including its territories and possessions, any state of the United States and the District of Columbia).This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the 'Securities Act'). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia Canada, Japan, Hong Kong or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company, DNB Markets, Arctic Securities nor SpareBank1 Markets assumes any responsibility in the event there is a violation by any person of such restrictions.The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Link to prospectus click here

Link to announcement in pdf

Bionor Pharma ASA published this content on 13 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 January 2017 07:25:06 UTC.

Original documenthttp://www.bionorpharma.com/en/Media/News/2016/Financial/Solon+Eiendom+ASA+–+Publication+of+prospectus%2C+listing+of+new+shares+and+start+of+subscription+perio.b7C_wlHG3U.ips

Public permalinkhttp://www.publicnow.com/view/DDF15CE8EB4F4349362E77743C969229BBFEB6C8